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Introduction
Cancer is the second most frequent cause of death in the world 
[1]. The discovery of antitumor activity of cisplatin began a search 
for other metal complexes with cytotoxic properties against 
cancer cells. One of the transition metal, whose complexes are 
extensively tested for antitumor application is copper. Copper is 
a trace element essential for human life. It is a building element of 
several important enzymes (e.g. superoxide dismutase, cytochrome 
oxidase, tyrosinase) and it regulates the intracellular redox potential, 
while its complexes possess antibacterial, antifungal, antiviral, anti-
inflammatory and anticancer properties. As potential anticancer 
drugs, there are currently extensively studied mainly complexes 
of copper(II). There are only few complexes of copper(I) in the 
literature, whereas they also show a very strong cytotoxic activity 
against tumor cells in vitro [2].
Anticancer activity of copper
Over 95% of copper (both Cu(II) and Cu(I)) that is present 
in serum is bound to ceruloplasmin (ferroxidase). However, it is 
not responsible for transporting copper inside the cell. Before they 
enter the cell, copper(II) ions are reduced to copper(I) by metalo-
reducatases located on the cell’s surface. Cu+ ions are transported 
into the cell mainly by a specific copper transporter (hCtr). The 
independent system of entering the cell, enables biologically active 
copper compounds to penetrate the cell surface without binding 
to other agents as opposite to coordination compounds of other 
metals [2÷4].
Anticancer activity of copper(I) compounds may be a result of 
different mechanisms. They are described in the following paragraphs 
of this review.
Anticancer activity of copper complex compounds is related 
to their ability to produce reactive oxygen species (ROS). Copper(I) 
ions can reduce hydrogen peroxide to hydroxyl radical. Copper(II) 
ions may in turn be reduced to Cu(I) by superoxide anion(O2
•-), 
or glutathione. Therefore, it can be concluded that the production 
of reactive oxygen species such as OH• are driven by the copper, 
regardless of the form in which it is initially introduced into the body 
– Cu+, or Cu2+ [2, 5].
Cu2+ + O2
•–  →  Cu+ + O2
Cu+ + H2O2  →  Cu2+ + OH• + OH–
Superoxide anion (O2
•-) is the product of reduction of the 
molecular oxygen that occurs in many biological processes. It is 
converted into hydrogen peroxide through dismutation. Both 
of these forms of ROS lead to the formation of another type of 
reactive oxygen species – the hydroxyl radical (OH•). It occurs 
in a reaction catalysed by copper (or iron) ions. This radical is 
believed to be the main factor causing DNA damage in cells under 
oxidative stress [6].
Copper compounds are also thought to have nuclease activity. 
The ability of copper to cut a DNA helix has been proved in studies 
conducted with the use of Cu(I) complexes with two molecules 
of 1,10-phenanthroline (phen). [Cu(phen)2]
+ was initially non-
covalently bound to DNA. In this form, it was oxidized to a copper(II) 
compound in the presence of hydrogen peroxide. The final result of 
those processes was cutting DNA or RNA strands into fragments. 
The postulated factor directly responsible for cutting the DNA 
was an adduct in which [Cu(phen)2]
2+ was coordinated with the 
hydroxyl radical OH• and linked by non-covalent interactions 
with DNA [7, 8].
Copper compounds coordinated to phenanthroline skeleton 
ligands (see Fig. 1), such as [Cu(dmp)2]
+, are thought to have the ability 
of intercalation. Furthermore, it was indicated that the [Cu(dmp)2]
+ 
(dmp=2,9-dimethyl-1,10-phenanthroline) can be an inhibitor of the 
process of DNA transcription [9]. The [Cu(bcp)2]
+ (bcp=2,9-dimethyl-
4,7-diphenyl-1,10-phenanthroline) is in turn believed to possess the 
ability of forming bridges between double-stranded fragment of DNA 
and another fragment of such a type [10].
Selected cuprous complexes
Selected complexes of copper(I), which were extensively 
investigated for anticancer activity, are presented in the subsequent 
paragraphs. Diversity of ligands used to synthesize those complexes 
causes that each one could possess other mechanism of action.
Mononuclear compounds
In 1987 Berners-Price and co-workers [11] presented copper(I) 
complexes with molecular formula [Cu(P-P)2]Cl, where central Cu
+ 
ion was coordinated with two molecules of bidentate phosphine. The 
structures of these complexes are presented in Figure 1.
Fig. 1. The structures of copper(I) complexes with bidentate phosphine
Cytotoxicity of compounds 1B and 1C are several times higher than 
the one presented by uncoordinated ligands tested in the same cell line. 
Compound 1D possesses anticancer activity (only in vitro), however 
it is lower than in 1B and 1C. Moreover, 1C also possesses in vivo 
anticancer activity. Additionally, the equilibrium between mononuclear 
[Cu(dppe)2]Cl and binuclear form (CuCl)2(dppe)3 is observed in 1A 
solution. For this reason cytotoxicity cannot be unambiguously assigned 
to mononuclear [Cu(dppe)2]Cl [11].
In order to increase solubility of copper(I) complexes in 
water, Marzano et al. introduced the hydroxyl groups to analysed 
phosphines. It is worth to mention that introduction of OH does not 
destabilize cuprous complexes. Structure of copper(I) complex ion 
of compound [Cu(thp)4][PF6] (2), synthesized by the same research 
group, is shown in Figure 2. In this compound central ion Cu+ is 
coordinated with four molecules of tris(hydroxymethyl)phosphine.
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Fig. 2. Complex ion of the compound [Cu(thp)4][PF6]
[Cu(thp)4][PF6] exhibits even 40-fold higher cytotoxicity than 
cisplatin (e.g. for colorectal adenocarcinoma cell line CaCo-2: 
IC50 =1.08 ± 0.12 µM for 2, IC50 = 35.42 ± 1.40 µM for cisplatin; 
48-hours test) [12]. Moreover, in survey performed on cancer cells 
of a colon 2 reacts selectively with cancer cells, but at the same 
time it is not harmful for healthy cells. The selectivity is higher than 
the one observed at cisplatin or oxaliplatin – the drug applied in 
colorectal cancer treatment (e.g. for non-tumour human fibroblasts 
cell line MRC-5: IC50 = 32.67 ± 1.34 µM for 2, IC50 = 19.66 ± 1.31 
µM for cisplatin and IC50 =23.93 ± 1.35 µM for oxaliplatin; 72-hours 
test) [13]. What is more, this compound is effective in case of those 
types of cancer which are resistant to platin complexes (e.g. for 
colon carcinoma cell line LoVo IC50=2.05 ± 0.43 µM for oxaliplatin, 
1.37 ± 0.35 µM for compound 2, whereas for resistant to oxaliplatin 
cell line LoVo-OxPt IC50=10.89 ± 1.34 µM for oxaliplatin and 
IC50=1.46 ± 0.27 µM for 2; 48-hours assay) [13]. The described 
complex of copper leads to cell death via nonapoptotic way (so-called 
type III cell death). Cell death is not caused by DNA fragmentation. 
What is more, activation of caspases does not take place. On the 
contrary, 2 may even inhibit caspases 3 and 7. Characteristic of 
this type of cell death are: massive cytoplasmic vacuolization, 
endoplasmic reticulum stress and inhibition of proteasome 26S 
functions. Furthermore, an increased production of reactive oxygen 
species (ROS) was observed, which caused an oxidative stress and 
led cells to death. It was unexpected that the complex [Cu(bhpe)2]
[PF6] synthesized by the same research group (Fig. 3), where 
monodentate phosphines were replaced by bidentate phosphines, 
would show only an inconsiderable anticancer activity. It was much 
lower not only than 2, but also than cisplatin (e.g. for colorectal 
adenocarcinoma cell line CaCo-2: IC50 = 52.50 ± 0.81 µM for 3, 
IC50 = 1.08 ± 0.12 µM for 2, IC50 = 35.42 ± 1.40 µM for cisplatin; 
48-hours test) [12].
The reason for an insignificant cytotoxicity of compound 3 could 
be its high stability and inertness in process of ligands exchange. It 
could be confirmed by results obtained from a mass spectrometry. 
For complex 3 no fragmentation was observed, as opposed to 2, in 
whose spectrum not only [Cu(thp)4]
+ ion peak was observed, but also 
peaks ascribed to [Cu(thp)3]
+ and [Cu(thp)2]
+. It can be concluded that 
ability to exchange ligands has crucial influence for cytotoxicity of the 
described complexes [12,13].
Fig. 3. Complex ion of compound [Cu(bhpe)2][PF6]
Anticancer activity is exhibited by copper(I) complexes possessing 
pyridine-type ligands (pyridine, bipyridine, phenanthroline ect.), 
or such where copper(I) ion is coordinated to phosphine ligands. 
Presumably, introduction of both types of ligands mentioned to one 
molecule would make it possible to create a compound with an 
increased activity against cancer cells. Marzano research group, 
mentioned before, synthesized complexes depicted in Figure 4, 
which contained triazolylborate ligands.
Fig. 4. Complexes of Cu+ with triazolylborate ligands
These compounds present activity higher than the one observed 
at cisplatin for all cell lines tested (Tab. 1), especially for lung adeno-
carcinoma cells (A549 cell line), where the IC50 value was approxi-
mately 17-fold lower for compound 4B (IC50 = 2.35 ± 0.9 µM) and 
26-fold lower for complex 4A (IC50=1.52 ± 0.7 µM), than for tested 
in the same condition cisplatin (IC50=39.27 ± 1.9 µM; 48-hours test) 
[14]. The mechanism of the action has been unknown so far. Howe-
ver, it is posited that it could be similar to that exhibited by copper(I) 
complex showed in Figure 5.
Fig. 5. Complex of Cu(I) leading to cell death in a nonapoptotic way
Compound 5 exhibits activity from 2 to 19 times higher than 
cisplatin for investigated cell lines (e.g. for breast cancer cell line 
MCF-7 IC50=1.55 ± 0.19 µM for 5 and IC50 = 30.18 ± 1.5 µM for 
cisplatin; 48-hours test) [15]. In vitro tests suggest that the complex 
mentioned leads to cell death in a nonapoptotic pathway, as it was 
observed at[Cu(thp)4][PF6] (2). Lack of caspase 3 activity, an increase in 
a cell size and a cytoplasmic vacuolization confirm this hypothesis [15].
Other interesting compound revealing much higher cytotoxicity 
than cisplatin is a coordination compound of copper(I) displayed in 
Figure 6 (e.g. for colon carcinoma cell line HCT-15 IC50=1.05 ± 0.31 µM 
for 6 and IC50 = 16.65 ± 2.63 µM for cisplatin) [16].
Fig. 6. Electrically neutral copper(I) complex
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Due to the fact that the applied tridentate ligand simultaneously 
neutralizes positive charge of Cu+ ion, the received compound 6 is 
electrically neutral. A mechanism of cellular internalization has not been 
explained so far. It is assumed that penetration of a cell membrane is not 
supported by human copper transporters (hCtr), which can transfer 
positively charged molecules. As the authors postulate, a dentate 
ligand could be the factor, which supports complexes’ transfer. It acts 
as ionophore, as it was the case with copper(II) complexes [16, 17].
Coordination number 4 is not the only one possible coordination 
number for copper(I) complexes. In Figure 7 a two-coordinated 
compound of Cu+ is depicted. In vitro cytotoxic activity of the presented 
compound was approximately 2,5-fold higher than the one measured 
for cisplatin. What is remarkable, this effect was also observed for cell 
lines resistant to cisplatin (e.g. for sensitive to cisplatin human ovarian 
cancer cell line 2008 IC50 = 1.84 ± 0.32 µM for 7 and 3.12 ± 1.03 
µM for cisplatin; in case of resistant to cisplatin human ovarian cancer 
cell line C13* IC50 is 2.08 ± 0.72 for 7 and 22.18 ± 2.01 for cisplatin; 
72-hours assay) [18]. Presumably, mechanism of activity of compound 8 
is connected with its confirmed ability to disturb respiration by altering 
mitochondrial membrane potential and producing reactive oxygen 
species [18].
Fig. 7. Two-coordinated complex of Cu(I)
Starosta et al. [19÷24] synthesized copper(I) complexes, whose 
general structure is displayed in Figure 8.
Fig. 8. General structure of copper(I) complexes containing 
phosphine, phenanthroline-type ligand and iodide ion
The obtained complexes show high cytotoxicity not only to human 
ovarian carcinoma cell lines sensitive to cisplatin, but also to those 
resistant to this drug (for resistant to cisplatin human ovarian carcinoma 
cell line SKOV 3 IC50 is approximately 2–3 µM depending on examined 
copper(I) compounds, whereas for cisplatin IC50 = 180.5 ± 9.3 µM; 
for sensitive to cisplatin human ovarian carcinoma cell line MDAH 
2774 IC50 is approximately 2–7 µM for analysed copper(I) complex and 
77.2±7.6 µM for cisplatin; 24-hours test) [19]. As the authors proved, 
activity exhibited by investigated cuprous compound is many times 
higher than the one presented by uncoordinated diimine or phosphine 
ligands (IC50:100–500 µM in case of both cell lines: SKOV 3 and MDAH 
2774) [19÷24].
Polinuclear compounds
In 2010 Balakrishna and co-workers [25] exhibited group of 
polinuclear copper(I) complexes, which possessed in their coordination 
sphere both pyridine-type and phospine-type ligands. In Figures 9 and 
10 examples of synthesized compounds are depicted.
Fig. 9. Binuclear copper(I) complexes synthesized by Balakrishna et al
Fig. 10.Octanuclear Cu+ compound synthesized by Balakrishna et al
Antiproliferative activity for cervical cancer cells was proved 
for all three copper complexes presented in Figures 10 and 11. 
Moreover, it was observed that inhibition of proliferation was more 
effective for the complexes discussed, than for cisplatin, especially 
for 9B (antiproliferative ability was assessed as a percent of inhibition 
of cervical cancer HeLa cell line proliferation: 50 ± 4 % for 9A, 
62 ± 9 % for 10, 100 % for 9B and 49 ± 7 % for cisplatin; in 
10 µM concentration) [25]. Biological tests carried out with the use of 
this complex show that 9B inhibits proliferation not only of cervical 
cancer cells, but also of human breast cancer cells and Chinese 
hamster ovary cells. Moreover, it is several times more efficient 
than cisplatin. Furthermore 9B has an ability to damage the DNA 
integration, block cell cycle in G1 phase and induce apoptosis [25].
Another interesting binuclear cuprous compound revealing 
anticancer activity, is depicted in Figure 12 complex with formula 
[Cu2(dppe)3(CH3CN)4](ClO4).
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Fig. 11. [Cu2(dppe)3(CH3CN)4](ClO4)2
The anticancer activity of compound 11 was confirmed by tests 
carried out on several cell lines (Table 1) [26]. 11 managed to damage 
DNA helix, inhibit processes of its synthesis, stop cell cycle in G1 and 
G2 phases and induce apoptosis. If 11 and adriamycin (drug in cancer 
therapy) are used simultaneously in treatment, synergism of action is 
observed. 11 increases therapeutic effect of adriamycin and vice versa. 
It is believed that 11 binds to DNA by displacement of acetonitrile 
molecules. Simulations with a use of molecular modelling methods imply 
that the most profitable donor of a pair of electrons is the atom N7 
of guanine. Since in one molecule of 11 two Cu+ ions are present, the 
discussed copper(I) complex acts as chelate agent. It creates two bonds 
with DNA, as a result of replacement of two acetonitrile molecules for 
two guanine molecules of deoxyribonucleic acid. Mutual strengthening 
of anticancer activity between 11 and adriamycin suggests that both 
agents bind to other helix regions. Moreover each one causes changes 
in DNA in a way that facilitates binding of the second one [27].
Summary
Mechanisms of anticancer activity discussed in this article are 
presented on Scheme 1. Copper(I) coordination compounds described 
in this review are in turn collected in Table 1. It summarises their biological 
activity and types of cell line, in which complexes were tested in vitro.
Copper(I) compounds may become an alternative for cisplatin, 
which possesses a few drawbacks but is still most popular. Copper, as an 
essential element for human life is supposed to be less toxic than other 
metals, like platinum or ruthenium, analysed for medical application. 
Both copper ions, Cu+ and Cu2+ can induce oxidation stress via catalysis 
and production of reactive oxygen species. Superiority of copper(I) 
compounds over copper(II) compounds results from nuclease activity of 
Cu+ complexes and selectivity exhibited by human copper transporters 
(hCtr) in introduction of Cu+ ions to cells. Copper as an antibacterial 
agent is used in hospitals, health centres and public buildings for various 
sanitary applications (for instance handles, holders, handrails ect.) [28]. 
As it was presented in this article, copper(I) coordination compounds 
have remarkable application potential. Intensive research may enable 
to finally apply them as anticancer drugs.
Scheme 1. Selected examples of anticancer activity and mode  
of action of Cu(I) complexes
Table 1
Biological activity of described cuprous complexes
Cu(I) 
compound
Cancer cell line, in which 
investigations were performed
Biological activity Lit.
1C
P388 (mouse leukemia)• 
B16 (melanoma)• 
M5076 (reticulum cell sarcoma)• 
probably DNA damages, • 
single-strand breaks in 
supercoiled plasmid-DNA 
in vitro
11
2
A549 (lung carcinoma)• 
MCF-7 (breast carcinoma)• 
HepG2 (liver carcinoma)• 
CaCo-2, HCT-15, LoVo , DLD1, • 
SW480 (colon cancer)
HeLa (cervix carcinoma)• 
A375 ( melanoma)• 
Daudi (Brukitt lymphoma)• 
HL60 (promyelocytic leukemia)• 
strong antiproliferative • 
activity
reactive oxygen species • 
production
nonapoptotic cell death • 
(inhibitionof caspases 
3 and 7) - cytoplasmic 
vacuolization, endoplasmic 
reticulum stress, proteasome 
26S inhibition)
12
13
4A, 4B
A549 (lung adenocarcinoma)• 
A375 ( melanoma)• 
HL60 (promyelocytic leukemia)• 
A431 (cervix cancer)• 
2008 (ovarian cancer)• 
changes in redox potential • 
of cell membrane which is 
the result of disruption in 
oxidative phosphorylation 
process
14
5
A549 (lung carcinoma)• 
HL60 (promyelocytic leukemia)• 
MCF-7 (breast carcinoma)• 
A375 (melanoma)• 
LoVo (colon carcinoma)• 
nonapoptotic cell death • 
(caspase-3 activity was 
not observed, cytoplasmic 
vacuolisation and increase in 
cell size)
15
6
MCF-7 (breast carcinoma)• 
A549 (lung carcinoma)• 
A375 ( melanoma)• 
HL60 (promyelocytic leukemia)• 
HCT-15, LoVo (colon carcinoma)• 
A431 (cervix cancer)• 
2008, C13* (ovarian cancer)• 
mechanism still unknown• 
ligand acts as ionophore• 
16
7
HL60 (promyelocytic leukemia)• 
MCF-7 (breast cancer)• 
HCT-15 (colon carcinoma)• 
HeLa (cervix carcinoma)• 
A549 (lung carcinoma)• 
2008, C13* (ovarian cancer)• 
ability to disturb respiration • 
by altering mitochondrial 
membrane potential and 
producing reactive oxygen 
species
18
8
SKOV 3, MDAH 2774 (human • 
ovarian carcinoma)
mechanism unknown• 
19÷24
9A, 10 HeLa (cervical cancer)• antiproliferative activity 25
9B
HeLa (cervical cancer)• 
MCF-7 and MDA-MB 231 (breast • 
cancer)
CHO (Chinese hamster ovarian • 
cancer)
antiproliferative activity• 
ability to damage DNA • 
integrity
inhibition of cell cycle in G1 • 
phase
induction of apoptosis• 
25
11
H460 (lung cancer)• DNA damages• 
DNA synthesis inhibition• 
inhibition of cell cycle in G1 • 
phase
induction of apoptosis• 
synergetic enhancement • 
of activity when it is 
used simultaneously with 
adriamycin
26
27
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